Protagonist Other Current Liab from 2010 to 2025
| PTGX Stock | USD 49.56 1.49 2.92% |
Other Current Liabilities | First Reported 2014-12-31 | Previous Quarter 20.7 M | Current Value 23.7 M | Quarterly Volatility 11 M |
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 4.1 M or Selling General Administrative of 45.6 M, as well as many indicators such as Price To Sales Ratio of 5.2, Dividend Yield of 0.0 or PTB Ratio of 3.7. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
Protagonist | Other Current Liab |
Latest Protagonist Therapeutics' Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of Protagonist Therapeutics over the last few years. It is Protagonist Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Current Liab | 10 Years Trend |
|
Other Current Liab |
| Timeline |
Protagonist Other Current Liab Regression Statistics
| Arithmetic Mean | 9,905,500 | |
| Coefficient Of Variation | 120.66 | |
| Mean Deviation | 9,702,188 | |
| Median | 9,546,000 | |
| Standard Deviation | 11,951,679 | |
| Sample Variance | 142.8T | |
| Range | 46.6M | |
| R-Value | 0.69 | |
| Mean Square Error | 80.1T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 1,733,562 | |
| Total Sum of Squares | 2142.6T |
Protagonist Other Current Liab History
About Protagonist Therapeutics Financial Statements
Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Liabilities | 23.7 M | 14 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.